Azacitid
Generic Name
Azacitidine
Manufacturer
Hypothetical Pharma Inc.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| azacitid 300 mg tablet | ৳ 1,400.00 | ৳ 5,600.00 |
Description
Overview of the medicine
Azacitidine is an antimetabolite and a pyrimidine nucleoside analog that is used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It works by inhibiting DNA methyltransferase, leading to hypomethylation of DNA and restoration of normal cell function.
Uses & Indications
Dosage
Adults
300 mg orally once daily for 14 days of a 28-day cycle. Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.
Elderly
No specific dosage adjustment required for elderly patients, but careful monitoring is recommended.
Renal_impairment
Dose reduction may be required for severe renal impairment (CrCl <30 mL/min). Consult prescribing information for detailed guidance.
How to Take
Administer orally with or without food. Take at approximately the same time each day. Do not crush, cut, or chew the tablet.
Mechanism of Action
Azacitidine is a nucleoside metabolic inhibitor. It incorporates into DNA and RNA, leading to hypomethylation and cytotoxicity. In DNA, it inhibits DNA methyltransferases, leading to hypomethylation of DNA and restoration of gene function important for differentiation and proliferation. In RNA, it is thought to disrupt RNA function and synthesis.
Pharmacokinetics
Onset
Therapeutic effects may not be observed for several weeks or months.
Excretion
Excreted predominantly in the urine (approximately 50-85% of dose).
Half life
Approximately 14 hours (oral form).
Absorption
The oral formulation has a mean absolute bioavailability of approximately 11% compared to subcutaneous administration. Absorption is rapid, with peak plasma concentrations occurring within 0.5-4 hours.
Metabolism
Primarily metabolized by hydrolysis via cytidine deaminase, and then by hepatic deamination.
Side Effects
Contraindications
- •Known hypersensitivity to azacitidine or mannitol
- •Patients with advanced malignant hepatic tumors (caution advised)
Drug Interactions
Other myelosuppressive agents
Increased risk of bone marrow suppression. Monitor blood counts closely.
Drugs metabolized by cytidine deaminase (e.g., cytarabine)
Potential for altered metabolism and increased toxicity. Use with caution.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep in the original package to protect from moisture. Keep out of reach of children.
Overdose
No specific antidote. Management of overdose should be symptomatic and supportive, including monitoring of hematologic parameters and providing supportive care as needed.
Pregnancy & Lactation
Azacitidine can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. It is not known whether azacitidine or its metabolites are excreted in human milk. Advise lactating women to discontinue breastfeeding during treatment and for 1 week after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date.
Availability
Hospitals, specialized pharmacies
Approval Status
Approved (e.g., FDA, EMA)
Patent Status
Generic available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
